15 assets in Osteoarthritis

Therapeutic assets addressing Osteoarthritis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Duloxetine Osteoarthritis	The Catholic University of Korea	P4	BBB (72)
Dextrose Solution Osteoarthritis	Kastamonu University	P4	BB (69)
Triamcinolone Hexacetonide Osteoarthritis	Kastamonu University	P4	BB (69)
Pregabalin Osteoarthritis	The Catholic University of Korea	P3	B (62)
Eloralintide Osteoarthritis	Eli Lilly and Company	P3	B (60)
Orforglipron Osteoarthritis	Eli Lilly and Company	P3	B (60)
ly3857210 Osteoarthritis	Eli Lilly and Company	P2	B (57)
(S)-2-(3-Methyl-1-((3-Methyl-1,2,4-Oxadiazol-5-Yl)Methyl)-2,6-Dioxo-1,2,3,6-Tetrahydro-7H-Purin-7-Yl)-N-(6-(2-(Trifluoromethyl)Pyrimidin-5-Yl)Pyridin-2-Yl)Propanamide Osteoarthritis	Eli Lilly and Company	P2	B (57)
Doxycycline Osteoarthritis	Campbell Clinic	P2	CCC (53)
in1011-n17 Osteoarthritis	iN Therapeutics Co., Ltd.	P1	CC (46)
in1011-n17 hcl Osteoarthritis	iN Therapeutics Co., Ltd.	P1	CC (43)
Kenacort Osteoarthritis	Haydarpasa Numune Training and Research Hospital	N/A	D (30)
L-Acetyl Carnitine Osteoarthritis	Khyber Medical University Peshawar	N/A	D (30)
Prilocaine Osteoarthritis	Haydarpasa Numune Training and Research Hospital	N/A	D (30)
Pipe-791 Osteoarthritis	Contineum Therapeutics	P1	NR ()